AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22068586 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional studies of p.D253H and p.T1173R mutations
Number of subjects: 47
Study 22068586 — intervention group
Group type: EXPERIMENTAL
Intervention: p.T1173R mutation
Number of subjects: 47
Study 22068586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality and disease progression
Number of subjects: 47
Study 22068813 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced diet (55 En% carbohydrates, 30 En% fat, 15 En% proteins) and exercise therapy once a week
Number of subjects: 453
Study 22068813 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced diet and exercise therapy
Number of subjects: 453
Study 22069451 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for children ≤5 years old, duration of 6 months.
Number of subjects: 184
Study 22069461 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated video gaming
Number of subjects: 282
Study 22070930 — intervention group
Group type: EXPERIMENTAL
Intervention: Toca 511 (non-lytic retroviral replicating vector)
Number of subjects: 0
Study 22070930 — intervention group
Group type: EXPERIMENTAL
Intervention: Toca 511
Number of subjects: 0
Study 22071596 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg/day
Number of subjects: 12
Study 22071596 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 20-50 mg/day
Number of subjects: 12
Study 22073145 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients (n = 9)
Number of subjects: 19
Study 22073145 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic rats with early death (n = 6)
Number of subjects: 19
Study 22073145 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic rats without early death (n = 10)
Number of subjects: 19
Study 22073145 — intervention group
Group type: COMPARATOR
Intervention: Sham-operated rats (n = 8)
Number of subjects: 19
Study 22074178 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g PinnoThin TAG
Number of subjects: 67
Study 22074178 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g PinnoThin TAG
Number of subjects: 67
Study 22074178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (milk fat)
Number of subjects: 67
Study 22074614 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated primary care network for prevention and management of cardiometabolic risk (PCMR)
Number of subjects: 3000
Study 22074813 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant + Parent Training
Number of subjects: 0
Study 22074813 — intervention group
Group type: COMPARATOR
Intervention: Stimulant + Antipsychotic (Risperidone) + Parent Training
Number of subjects: 0
Study 22075451 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents (BES)
Number of subjects: 1707
Study 22075451 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer sirolimus-eluting stents (SES)
Number of subjects: 1707
Study 22075481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic thermal vapour ablation (BTVA)
Number of subjects: 44
Study 22075927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve (TPV) implantation with the Melody valve
Number of subjects: 150
Study 22075927 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MSF
Number of subjects: 150
Study 22076476 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 48
Study 22077194 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous antibiotics
Number of subjects: 1744
Study 22077194 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative systemic antibiotic therapy (68.7% of patients)
Number of subjects: 1744
Study 22077194 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hematomas
Number of subjects: 1744
Study 22077194 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine for topical antisepsis (used by sites with infection rates >5%)
Number of subjects: 1744
Study 22078072 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 496
Study 22078932 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib 0.25 mg/kg/day
Number of subjects: 53
Study 22078984 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal %VLFI (>4%)
Number of subjects: 428
Study 22078984 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender, increased body mass index, ambulatory systolic BP
Number of subjects: 428
Study 22078984 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 428
Study 22079051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Shot 3D-CRT Partial Breast Irradiation (SSPBI) with a dose of 21 Gy
Number of subjects: 64
Study 22079305 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPCR
Number of subjects: 227
Study 22079305 — intervention group
Group type: COMPARATOR
Intervention: Culture
Number of subjects: 227
Study 22079876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular infusion of a combination cell product
Number of subjects: 26
Study 22079961 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold diode laser MicroPulse (SDM)
Number of subjects: 52
Study 22079961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg bevacizumab (BCZ)
Number of subjects: 52
Study 22079961 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 52
Study 22080223 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with SBP ≤ 140 mmHg
Number of subjects: 994
Study 22080223 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with orthostatic hypotension
Number of subjects: 994
Study 22080223 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with well-controlled BP (SBP < 140 mmHg)
Number of subjects: 994
Study 22080332 — intervention group
Group type: EXPERIMENTAL
Intervention: RVI detected by cardiac magnetic resonance
Number of subjects: 450
Study 22080332 — intervention group
Group type: EXPERIMENTAL
Intervention: High RV myocardial mass
Number of subjects: 450
Study 22080332 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Thrombolysis In Myocardial Infarction flow before angioplasty
Number of subjects: 450
Study 22080332 — intervention group
Group type: COMPARATOR
Intervention: Major adverse cardiac event (composite of death, reinfarction, and congestive heart failure)
Number of subjects: 450
Study 22080707 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) A1c test
Number of subjects: 237
Study 22080838 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide significant locus on chromosome 19q13 (rs7937)
Number of subjects: 3499
Study 22080838 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of SNP rs7937 in 2859 subjects from ICGN
Number of subjects: 3499
Study 22080838 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of SNP rs2604894 in 2859 subjects from ICGN
Number of subjects: 3499
Study 22081446 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scanning
Number of subjects: 489
Study 22081446 — intervention group
Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 489
Study 22081446 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 489
Study 22081446 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning and Radiography
Number of subjects: 489
Study 22082029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) cultured in CellGenix DC media containing 2% human AB serum
Number of subjects: 0
Study 22082029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) harvested using recombinant trypsin
Number of subjects: 0
Study 22082029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) preserved with an infusible cryomedia
Number of subjects: 0
Study 22082029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) activated for 16 hours with LPS and IFN-γ
Number of subjects: 0
Study 22082722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex with both men and women (AAWSWM)
Number of subjects: 196
Study 22083160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hutchinson-Gilford progeria syndrome patients
Number of subjects: 0
Study 22084160 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial detachment of one-third or less of the graft surface area (n = 16; group 1)
Number of subjects: 150
Study 22084160 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial detachment of more than one-third of the graft surface area (n = 8; group 2)
Number of subjects: 150
Study 22084160 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft positioned upside down (n = 4; group 3)
Number of subjects: 150
Study 22084160 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-floating Descemet roll in the host anterior chamber (n = 8; group 4)
Number of subjects: 150
Study 22084160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall graft detachment (partial or complete)
Number of subjects: 150
Study 22084160 — intervention group
Group type: EXPERIMENTAL
Intervention: Detachment causes
Number of subjects: 150
Study 22086847 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT imaging at 12 weeks after CRT completion
Number of subjects: 99
Study 22086847 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment at 12 weeks after CRT completion
Number of subjects: 99
Study 22086847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PET/CT and clinical assessment
Number of subjects: 99
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcium channel blockade as monotherapy or combination therapy
Number of subjects: 216
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 216
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic PAH/familial PAH
Number of subjects: 216
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH associated with congenital heart disease
Number of subjects: 216
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at diagnosis
Number of subjects: 216
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pulmonary vascular resistance index, lower-weight z scores, familial PAH
Number of subjects: 216
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute vasoreactivity
Number of subjects: 216
Study 22086881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower brain natriuretic peptide
Number of subjects: 216
Study 22087267 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine
Number of subjects: 1052
Study 22087555 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual at inpatient family clinics
Number of subjects: 102
Study 22087555 — intervention group
Group type: COMPARATOR
Intervention: Community parents (n = 439)
Number of subjects: 102
Study 22088584 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia-derived HCA
Number of subjects: 48
Study 22088584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22088784 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning (three different positions for 4 hours each)
Number of subjects: 29
Study 22088784 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning (before and after feeding)
Number of subjects: 29
Study 22088989 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (dual MET/ALK inhibitor)
Number of subjects: 3
Study 22089184 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi Wave Animator (MWA) tool used for dynamic visualization of hemodynamic and ventilator data during cardiac arrest and resuscitation.
Number of subjects: 0
Study 22089184 — intervention group
Group type: EXPERIMENTAL
Intervention: Video analysis of cardiac arrest and resuscitation events using MWA.
Number of subjects: 0
Study 22089462 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A H1N1/2009 vaccine
Number of subjects: 237
Study 22090362 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 0332991 at 125 mg once daily
Number of subjects: 41
Study 22090362 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 0332991
Number of subjects: 41
Study 22090469 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic Index (GI) of breakfast meals
Number of subjects: 57
Study 22090469 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Area Under the Curve (iAUC) after the OGTT
Number of subjects: 57
Study 22090469 — intervention group
Group type: EXPERIMENTAL
Intervention: Available Carbohydrate (avCHO) content of breakfast meals
Number of subjects: 57
Study 22090469 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 57
Study 22090469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat, protein, dietary fiber, age, sex, and BMI
Number of subjects: 57
Study 22092012 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 21
Study 22093200 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine diphosphate (ADP) receptor inhibitors
Number of subjects: 17000
Study 22093200 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care platelet inhibition testing
Number of subjects: 17000
Study 22093200 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly reports to participating sites
Number of subjects: 17000
Study 22093207 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study 22093206 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO) measured at arrival with a cutpoint of 210 ng/mL
Number of subjects: 1018
Study 22093206 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO)
Number of subjects: 1018
Study 22093210 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (BES)
Number of subjects: 56
Study 22093210 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 56
Study 22093210 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison at 24 months
Number of subjects: 56
Study 22093579 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 12 weeks
Number of subjects: 879
Study 22093579 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 879
Study 22094934 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative paclitaxel (80 mg/m²) and gemcitabine (1,200 mg/m²) with weekly trastuzumab for 6 cycles, followed by 1 year of trastuzumab and 5 years of hormone therapy if indicated.
Number of subjects: 53
Study 22094934 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative paclitaxel, gemcitabine, and trastuzumab (PGH) combination therapy.
Number of subjects: 53
Study 22095114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention
Number of subjects: 401
Study 22095114 — intervention group
Group type: COMPARATOR
Intervention: Hypoenergetic diet program
Number of subjects: 401
Study 22095837 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 26
Study 22096242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline hemoglobin concentration
Number of subjects: 814
Study 22096242 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline systolic blood pressure
Number of subjects: 814
Study 22096242 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 814
Study 22097928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette-related pictures
Number of subjects: 35
Study 22097928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant pictures (erotica and romance)
Number of subjects: 35
Study 22097928 — intervention group
Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 35
Study 22098110 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha (Erypo®) intravenously (300 U/kg)
Number of subjects: 12
Study 22098628 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label component of the STEP-BD
Number of subjects: 3399
Study 22098628 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical characteristics
Number of subjects: 3399
Study 22098676 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study 22100149 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module A)
Number of subjects: 48
Study 22100149 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 6), paclitaxel 200 mg/m2, and bevacizumab 15 mg/kg for 4 cycles (Module B)
Number of subjects: 48
Study 22100149 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module C)
Number of subjects: 48
Study 22102646 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/day intravenous undiluted alanyl-glutamine
Number of subjects: 88
Study 22102646 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 88
Study 22102709 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 39
Study 22102709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification therapy
Number of subjects: 39
Study 22102709 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular remission
Number of subjects: 39
Study 22102709 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction minimal residual disease detection
Number of subjects: 39
Study 22102709 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular remission after induction chemotherapy
Number of subjects: 39
Study 22104457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624
Study 22104457 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study 22104544 — intervention group
Group type: EXPERIMENTAL
Intervention: %VLFI of 2.4%
Number of subjects: 832
Study 22104544 — intervention group
Group type: EXPERIMENTAL
Intervention: %VLFI of 4%
Number of subjects: 832
Study 22105591 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg/d
Number of subjects: 74
Study 22105591 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 600-800 mg/d
Number of subjects: 74
Study 22105720 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 3-AP at 150 mg per dose
Number of subjects: 20
Study 22105720 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 3-AP at 100 mg
Number of subjects: 20
Study 22105799 — intervention group
Group type: EXPERIMENTAL
Intervention: AOSLO imaging and functional testing
Number of subjects: 4
Study 22105799 — intervention group
Group type: EXPERIMENTAL
Intervention: AOSLO imaging
Number of subjects: 4
Study 22105799 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional testing (ffERG, mfERG, SD-OCT)
Number of subjects: 4
Study 22105799 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-retinal antibody analysis
Number of subjects: 4
Study 22105801 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular ACI7000PDT corneal inlay implantation
Number of subjects: 24
Study 22105894 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate at a dose of 400 mg/day for 1 year after surgery
Number of subjects: 64
Study 22106236 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid and pulsed dye laser
Number of subjects: 23
Study 22106377 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, on-site standard (10 h) dose of Road Tour training
Number of subjects: 681
Study 22106377 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, on-site standard dose of Road Tour training with 4 h of subsequent booster training
Number of subjects: 681
Study 22106377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered, at-home standard dose of Road Tour training
Number of subjects: 681
Study 22106377 — intervention group
Group type: COMPARATOR
Intervention: Supervised, on-site standard dose of attention control (crossword puzzles) training
Number of subjects: 681
Study 22106730 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol ointment 3 microg/g applied twice daily on weekdays and clobetasol propionate spray 0.05% applied twice daily on weekends for up to 4 weeks
Number of subjects: 0
Study 22106941 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 410
Study 22106941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 22108357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching or Bangerter filters
Number of subjects: 633
Study 22109661 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time magnetic resonance-guided laser-induced thermal therapy (MRgLITT)
Number of subjects: 7
Study 22110067 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution macular imaging using adaptive optics scanning laser ophthalmoscopy (AOSLO) and spectral domain optical coherence tomography (SD-OCT)
Number of subjects: 29
Study 22110067 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity, kinetic and static perimetry, fundus-guided microperimetry, full-field electroretinography (ERG), and multifocal ERG
Number of subjects: 29
Study 22110067 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequencing of the RS1 gene
Number of subjects: 29
Study 22110067 — intervention group
Group type: COMPARATOR
Intervention: Control group of 27 age-similar healthy subjects
Number of subjects: 29
Study 22110076 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-light FAF images (514 nm)
Number of subjects: 95
Study 22110076 — intervention group
Group type: COMPARATOR
Intervention: Blue-light FAF images (488 nm)
Number of subjects: 95
Study 22110166 — intervention group
Group type: COMPARATOR
Intervention: Low-dose bacterial endotoxin
Number of subjects: 0
Study 22110166 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe blunt trauma
Number of subjects: 0
Study 22110211 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 40
Study 22110211 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 40
Study 22110246 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc 1 IU/kg
Number of subjects: 14
Study 22110246 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc 5 IU/kg
Number of subjects: 14